Effect Analysis of Ulinastatin Injection Combined with Xuebijing Injection in the Treatment of Severe Pneumonia Sepsis

LI Dan; YANG Xiaoting; ZHAO Lixiao; ZHANG Nan; SU Haiyan; WANG Yan; ZHAO Lijun

doi:10.3969/j.issn.1002-3429.2025.14.008

Abstract：Objective To explore the therapeutic effect of Ulinastatin injection combined with Xuebijing injection in patients with severe pneumonia sepsis(SPS).Methods Forty patients with SPS admitted from September 2022 to October 2023 were selected and randomly divided into two groups by random number table method.The control group was treated with Ulinastatin injection on the basis of conventional treatment,while the observation group was treated with Xuebijing Injection on the basis of the control group.Both groups were treated continuously for 14 d.Clinical efficacy and the occurrence of adverse reactions during the treatment,as well as serum procalcitonin(PCT),neutrophil-to-lymphocyte-to-platelet ratio(NLPR),serum creatinine(Scr),cystatin C(Cys-C),high mobility group protein B1(HMGB1),Toll-like receptor 4(TLR4),monocyte chemoattractant protein-1(MCP-1),and thrombin time(TT),activated partial thromboplastin time(APTT),fibrinogen degradation products(FDP),fibrinogen(FIB),prothrombin time(PT),and Acute Physiology and Chronic Health Evaluation Ⅱ(APACHE Ⅱ)score before and after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group was 95.0%(19/20),which was higher than that of the control group(70.0%,14/20),and the difference was statistically significant(P<0.05).After treatment,the levels of PCT,NLPR,Scr,Cys-C,HMGB1,TLR4 and MCP-1 in both groups decreased,which were lower in the observation group than in the control group(P<0.05).After treatment,TT,FDP and FIB in both groups decreased,while APTT and PT increased.Moreover,the change of the above indicators in the observation group was greater than that in the control group(P<0.05).The APACHEⅡscore of the observation group was lower than that of the control group at 3 d and 5 d after treatment(P<0.05).During the treatment period,there was no difference in adverse reactions between the observation group and the control group(P>0.05).Conclusion The combined use of Ulinastatin and Xuebijing injection for the treatment of SPS patients has a better effect,which can significantly reduce the levels of PCT,NLPR,Scr,Cys-C,HMGB1,TLR4,and MCP-1 in patients,without significantly increasing the incidence of adverse reactions.